Catalyst

Slingshot members are tracking this event:

Phase 2b interim analysis of Aramchol for non-alcoholic steatohepatitis (NASH) due 2H 2016

Source Link:
http://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=10565735&type=HTML&symbol=GLMD&companyName=Galmed+Pharmaceuticals+Ltd.&formType=6-K&dateFiled=2015-11-09

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
GLMD Community voting in process
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Oct 05, 2017
Occurred Source:
http://onlinelibrary.wiley.com/doi/10.1002/hep4.1107/full
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 2b Interim, Aramchol, Nash, Non-alcoholic Steatohepatitis
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.